Monoclonal Antibody Targeting of Anti-Cancer Agents
The concept of targeting cytotoxic agents to tumour sites following linkage to antibodies has become more acceptable following the development of monoclonal antibodies which react with tumour associated antigens (1). These include anti-CEA monoclonal antibodies in colorectal cancer as well as antibodies designated 791T/36, 19–9 and 17–1A, which react with colon carcinoma-associated membrane antigens. Monoclonal antibodies have also been produced which react with other types of human cancer including malignant melanoma, bone and soft tissue sarcomas, and carcinomas of breast, ovary and lung (1).
KeywordsOsteogenic Sarcoma Colon Carcinoma Metastatic Tumour Antibody Conjugate Cancer Research Campaign
Unable to display preview. Download preview PDF.
- 1.R. W. Baldwin, and V. S. Byers, “Monoclonal Antibodies for Tumour Detection and Drug Targeting”, Academic Press, 1985.Google Scholar
- 2.J. W. Uhr, Immunotoxins: Harnessing Nature’s Poisons. J. Immunol. 133: 1 (1984).Google Scholar
- 3.R. W. Baldwin, Design and development of drug-monoclonal antibody 791T/36 tor cancer therapy, in: “Monoclonal Antibody Therapy of Human Cancer”, K. Foon, and A. C. Morgan, eds., Martinus Nijhoff, Boston, p. 23–56 (1985).Google Scholar
- 4.G. F. Rowland, and R. G. Simmonds, Effects of monoclonal antibody-drug conjugates on human tumour cell cultures and xenografts, in: “Monoclonal Antibodies for Tumour Detection and Drug Targeting”, R. W. Baldwin, and V. S. Byers, eds., Academic Press, (1985).Google Scholar
- 8.N. C. Armitage, A. C. Perkins, J. D. Hardcastle, M. V. Pimm, and R. W. Baldwin, Monoclonal antibody imaging in malignant and benign gastrointestinal diseases, in: “Monoclonal Antibodies for Tumour Detection and Drug Targeting”, R. W. Baldwin, and V. S. Byers, eds., Academic Press (1985).Google Scholar
- 9.N. C. Armitage, A. C. Perkins, M. V. Pimm, R. W. Baldwin, and J.D. Hardcastle,11Imaging of primary and metastatic colorectal cancer using an In-labelled antitumour monoclonal antibody (791T/ 36). Nucl. Med. Comm., In press (1985).Google Scholar
- 10.L. G. Durrant, R. A. Robins, N. C. Armitage, A. Brown, R.W. Baldwin, J. D. Hardcastle, Association of antigen expression and DNA ploidy in colorectal tumours, Cancer Res., In press (1985).Google Scholar
- 11.K. C. Ballantyne, L. G. Durrant, N. C. Armitage, R. A. Robins, R.W. Baldwin, and J. D. Hardcastle, Monoclonal antibody binding to primary and metastatic colorectal cancer, Gut, 26:Abstr. 1154 (1985).Google Scholar
- 12.R. W. Baldwin, M. J. Embleton, J. Gallego, M. Garnett, M.W. Pimm, and M.R. Price, Monoclonal antibody drug conjugates for cancer therapy, in: “Monoclonal Antibodies for Diagnosis and Therapy of Cancer”, J. Roth, ed., Futura Publishing Co. (1986).Google Scholar
- 14.M.C. Garnett, and R. W. Baldwin, An improved synthesis of a methotrexate-albumin-791T/36 monoclonal antibody conjugate cytotoxic to osteogenic sarcoma cell lines, Cancer Res., In Press (1986).Google Scholar
- 15.G. F. Rowland, C. A. Axton, R. W. Baldwin, J. P. Brown, J. R. F. Corvalan, M. J. Embleton, V. A. Gore, I. Hellstrom, K. E. Hellstrom, E. Jacbos, C. H. Marsden, M. V. Pimm, R. G. Simmonds, and W. Smith, Anti-tumour properties of vindesin-monoclonal antibody conjugates, Cancer Immunol. Immunother. 19: 1 (1985).PubMedCrossRefGoogle Scholar